Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 4, 2022
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $25 on, Mar 4th, 2022
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $24 to $25 on, Mar 4th, 2022.
Mani has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $24 on, Tuesday, December 28th, 2021
